SSD

LOE Approaching

silver sulfadiazine

NDATOPICALCREAM
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

Pharmacologic Class:

Sulfonamide Antibacterial

Clinical Trials (5)

NCT06834009Phase 1Completed

A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists

Started Mar 2025
10 enrolled
Pain
NCT06718686Phase 1/2Recruiting

Rifaximin SSD in Dementia Trial

Started Dec 2024
20 enrolled
Dementia Alzheimer TypeDementia Associated With Cerebrovascular Disease
NCT05602025Phase 1Completed

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Started Dec 2022
140 enrolled
Asthma
NCT05297448Phase 3Active Not Recruiting

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Started Aug 2022
466 enrolled
Hepatic Encephalopathy
NCT05071716Phase 3Active Not Recruiting

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Started Apr 2022
524 enrolled
Hepatic Encephalopathy
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.